IDEAYA Biosciences, Inc. (IDYA) Earnings History

IDEAYA Biosciences, Inc. - Q4 FY2025 Earnings

Filed at: Feb 17, 2026, 6:04 AM EST|Read from source

EXECUTIVE SUMMARY

IDEAYA Biosciences reported a strong quarter of clinical execution and pipeline expansion, with significant progress in its darovasertib trials and IND clearances for new ADC candidates. The company ended the year with substantial cash reserves, positioning it to fund operations into 2030.

POSITIVE HIGHLIGHTS

  • •

    Cash, cash equivalents, and marketable securities of approximately $1.05 billion as of December 31, 2025, expected to fund operations into 2030.

    positive
  • •

    Collaboration revenue increased to $10.9 million for Q4 2025 from $7.0 million in Q4 2024, driven by the Servier license agreement.

    positive
  • •

    IND filings for IDE034 (B7H3/PTK7 bispecific TOP1 ADC) and IDE574 (KAT6/7 dual inhibitor) were cleared by the FDA.

    positive
  • •

    Full enrollment of 437 patients in the OptimUM-02 Phase 2/3 registrational trial for darovasertib and crizotinib combination completed.

    positive

CONCERNS & RISKS

  • •

    Net loss for Q4 2025 was $83.3 million, compared to $130.3 million in Q4 2024, indicating continued significant operating losses.

    negative
  • •

    Research and development expenses for Q4 2025 were $86.6 million, an increase from $140.2 million in Q4 2024, primarily due to a $75.0 million upfront payment in the prior year, but still representing substantial ongoing investment.

    attention
  • •

    General and administrative expenses increased to $18.8 million in Q4 2025 from $11.0 million in Q4 2024, driven by higher personnel, consulting, and legal fees.

    attention
  • •

    Net loss for the full year 2025 was $113.7 million, compared to $274.5 million in 2024, still reflecting substantial operating losses.

    negative

FINANCIAL METRICS

Revenue
Quarterly
$10.88M
+55.4%
Prior year: $7.00M
Annual (YTD)
$218.71M
N/A
Prior year: $7.00M
Net Income
Quarterly
$-83.27M
-36.1%
Prior year: $-130.31M
Annual (YTD)
$-113.70M
N/A
Prior year: $-274.48M
EPS (Diluted)
Quarterly
$-0.94
-36.9%
Prior year: $-1.49
Operating Income
Quarterly
$-94.57M
-34.4%
Prior year: $-144.14M
Annual (YTD)
$-159.31M
N/A
Prior year: $-326.98M
EPS (Basic)
Quarterly
$-0.94
-36.9%
Prior year: $-1.49

MARGIN ANALYSIS

Operating Margin
Current Quarter
-869.9%
Prior Year
-2059.1%
YoY Change
+1189 bps
Net Margin
Current Quarter
-765.6%
Prior Year
-1861.6%
YoY Change
+1096 bps

Margin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.

MANAGEMENT COMMENTARY

We had a strong quarter of clinical execution, clinical pipeline expansion and commercial readiness activities.

— IDEAYA Biosciences, Inc., Q4 FY2025 2025 Earnings Call

The key highlights include completing full enrollment of 437 patients in OptimUM-02, our Phase 2/3 registrational trial in first line HLA*A2-negative mUM, submission of IND filings for IDE034, a potential first-in-class B7H3/PTK7 bispecific TOP1 ADC, and IDE574, a KAT6/7 dual inhibitor, and continued build out of our U.S. commercial organization in anticipation of our upcoming topline PFS results.

— IDEAYA Biosciences, Inc., Q4 FY2025 2025 Earnings Call

Darovasertib is anticipated to be in three randomized, Phase 3 registrational trials across all stages of uveal melanoma by H1 ’26.

— IDEAYA Biosciences, Inc., Q4 FY2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.

OPERATIONAL METRICS

PFS events confirmed by BICR in OptimUM-02 trial
130
events

Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.